Paul Berns and Laura Deming
February 8, 2022 05:00 AM ESTUpdated 06:50 AM
Startups

Ex­clu­sive: ARCH-backed ex­er­cise-in-a-pill start­up qui­et­ly laid off half its staff, ‘ful­ly piv­ot­ed’ in Oc­to­ber

Jason Mast

Editor

In De­cem­ber 2019, a tiny decade-old Cal­i­for­nia start­up known as Cardero Ther­a­peu­tics an­nounced a new name — Epir­i­um Bio — a new di­rec­tion and $85 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times